

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)

0001614744

Name of Issuer

PURPLE BIOTECH LTD.

Jurisdiction of Incorporation/Organization

ISRAEL

Year of Incorporation/Organization

☒ Over Five Years Ago☐ Within Last Five Years (Specify Year)☐ Yet to Be FormedPrevious Names ☐ NoneKitov Pharma
Ltd.

Entity Type

☒ Corporation☐ Limited Partnership☐ Limited Liability Company☐ General Partnership☐ Business Trust☐ Other (Specify)

2. Principal Place of Business and Contact Information

Name of Issuer

PURPLE BIOTECH LTD.

Street Address 1

4 OPPENHEIMER STREET

Street Address 2

SCIENCE PARK

City

REHOVOT

State/Province/Country

ISRAEL

ZIP/PostalCode

7670104

Phone Number of Issuer

+972-3-933-3121

3. Related Persons

Last Name

Efron

First Name

Gil

Middle Name

Street Address 1

4 Oppenheimer Street

Street Address 2

Science Park

City

Rehovot

State/Province/Country

ISRAEL

ZIP/PostalCode

7670104

Relationship: ☒ Executive Officer ☐ Director ☐ Promoter

Clarification of Response (if Necessary):

Chief Executive Officer

Last Name

Fhima

First Name

Lior

Middle Name

Street Address 1

4 Oppenheimer Street

Street Address 2

Science Park

City

Rehovot

State/Province/Country

ISRAEL

ZIP/PostalCode

7670104

Relationship: ☒ Executive Officer ☐ Director ☐ Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name

Rowinsky

First Name

Eric

Middle Name

Street Address 1

4 Oppenheimer Street

Street Address 2

Science Park

City

Rehovot

State/Province/Country

ISRAEL

ZIP/PostalCode

7670104

Relationship: ☐ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

Chairman of the Board of Directors

Last Name

Israel

First Name

Isaac

Middle Name

Street Address 1

4 Oppenheimer Street

Street Address 2

Science Park

City

Rehovot

State/Province/Country

ISRAEL

ZIP/PostalCode

7670104

Relationship: ☐ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Rock	Simcha	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Agmon	Ido	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Gagnon	Robert	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Nahum-Zilberg	Suzana	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Herskovitz	Ori	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Reuveni	Hadas	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director <input type="checkbox"/> Promoter

Clarification of Response (if Necessary):

Vice President of Research and Development

Last Name	First Name	Middle Name
Schickler	Michael	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	

City
Rehovot
State/Province/Country
ISRAEL
ZIP/PostalCode
7670104
Relationship: ☒ Executive Officer ☐ Director ☐ Promoter

Clarification of Response (if Necessary):

Head of Clinical and Regulatory Affairs

Last Name	First Name	Middle Name
Morpurgo	Ido	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter	

Clarification of Response (if Necessary):

Vice President of Operations

Last Name	First Name	Middle Name
Margolin	Yael	
Street Address 1	Street Address 2	
4 Oppenheimer Street	Science Park	
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	7670104
Relationship:	<input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter	

Clarification of Response (if Necessary):

4. Industry Group

- | | | |
|---|---|--|
| <input type="checkbox"/> Agriculture | Health Care | <input type="checkbox"/> Retailing |
| Banking & Financial Services | <input checked="" type="checkbox"/> Biotechnology | <input type="checkbox"/> Restaurants |
| <input type="checkbox"/> Commercial Banking | <input type="checkbox"/> Health Insurance | Technology |
| <input type="checkbox"/> Insurance | <input type="checkbox"/> Hospitals & Physicians | <input type="checkbox"/> Computers |
| <input type="checkbox"/> Investing | <input type="checkbox"/> Pharmaceuticals | <input type="checkbox"/> Telecommunications |
| <input type="checkbox"/> Investment Banking | <input type="checkbox"/> Other Health Care | <input type="checkbox"/> Other Technology |
| <input type="checkbox"/> Pooled Investment Fund | <input type="checkbox"/> Manufacturing | Travel |
| Is the issuer registered as an investment company under the Investment Company Act of 1940? | Real Estate | <input type="checkbox"/> Airlines & Airports |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | <input type="checkbox"/> Commercial | <input type="checkbox"/> Lodging & Conventions |
| <input type="checkbox"/> Other Banking & Financial Services | <input type="checkbox"/> Construction | <input type="checkbox"/> Tourism & Travel Services |
| <input type="checkbox"/> Business Services | <input type="checkbox"/> REITS & Finance | <input type="checkbox"/> Other Travel |
| Energy | <input type="checkbox"/> Residential | <input type="checkbox"/> Other |
| <input type="checkbox"/> Coal Mining | <input type="checkbox"/> Other Real Estate | |
| <input type="checkbox"/> Electric Utilities | | |
| <input type="checkbox"/> Energy Conservation | | |
| <input type="checkbox"/> Environmental Services | | |
| <input type="checkbox"/> Oil & Gas | | |
| <input type="checkbox"/> Other Energy | | |

5. Issuer Size

- | | | |
|---|----|---|
| Revenue Range | OR | Aggregate Net Asset Value Range |
| <input type="checkbox"/> No Revenues | | <input type="checkbox"/> No Aggregate Net Asset Value |
| <input type="checkbox"/> \$1 - \$1,000,000 | | <input type="checkbox"/> \$1 - \$5,000,000 |
| <input type="checkbox"/> \$1,000,001 - \$5,000,000 | | <input type="checkbox"/> \$5,000,001 - \$25,000,000 |
| <input type="checkbox"/> \$5,000,001 - \$25,000,000 | | <input type="checkbox"/> \$25,000,001 - \$50,000,000 |
| <input type="checkbox"/> \$25,000,001 - \$100,000,000 | | <input type="checkbox"/> \$50,000,001 - \$100,000,000 |
| <input type="checkbox"/> Over \$100,000,000 | | <input type="checkbox"/> Over \$100,000,000 |

☒ Decline to Disclose

☐ Decline to Disclose

☐ Not Applicable

☐ Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

☐ Rule 504(b)(1) (not (i), (ii) or (iii))

☒ Rule 506(b)

☐ Rule 504 (b)(1)(i)

☐ Rule 506(c)

☐ Rule 504 (b)(1)(ii)

☐ Securities Act Section 4(a)(5)

☐ Rule 504 (b)(1)(iii)

☐ Investment Company Act Section 3(c)

☐ Section 3(c)(1)

☐ Section 3(c)(9)

☐ Section 3(c)(2)

☐ Section 3(c)(10)

☐ Section 3(c)(3)

☐ Section 3(c)(11)

☐ Section 3(c)(4)

☐ Section 3(c)(12)

☐ Section 3(c)(5)

☐ Section 3(c)(13)

☐ Section 3(c)(6)

☐ Section 3(c)(14)

☐ Section 3(c)(7)

7. Type of Filing

☒ New Notice

Date of First Sale 2024-07-01

☐ First Sale Yet to Occur

☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☐ Yes ☒ No

9. Type(s) of Securities Offered (select all that apply)

☐ Equity

☐ Pooled Investment Fund Interests

☐ Debt

☐ Tenant-in-Common Securities

☒ Option, Warrant or Other Right to Acquire Another Security

☐ Mineral Property Securities

☒ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

☐ Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$ 0 USD

12. Sales Compensation

Recipient

Recipient CRD Number ☐ None

H.C. Wainwright & Co., LLC

000000375

(Associated) Broker or Dealer ☒ None

(Associated) Broker or Dealer CRD Number ☒ None

Street Address 1

Street Address 2

430 Park Avenue

City

State/Province/Country

ZIP/Postal Code

New York

NEW YORK

10022

State(s) of Solicitation ☐ All States ☐ Non-US/Foreign

☐ AL ☐ AK ☐ AZ ☐ AR ☐ CA ☐ CO ☐ CT ☐ DE ☐ DC ☐ FL ☐ GA ☐ HI ☐ ID
☐ IL ☐ IN ☐ IA ☐ KS ☐ KY ☐ LA ☐ ME ☐ MD ☐ MA ☐ MI ☐ MN ☐ MS ☐ MO
☐ MT ☐ NE ☐ NV ☐ NH ☐ NJ ☐ NM ☒ NY ☐ NC ☐ ND ☐ OH ☐ OK ☐ OR ☐ PA
☐ RI ☐ SC ☐ SD ☐ TN ☐ TX ☐ UT ☐ VT ☐ VA ☐ WA ☐ WV ☐ WI ☐ WY ☐ PR

13. Offering and Sales Amounts

Total Offering Amount \$ 4,506,807 USD or ☐ Indefinite
Total Amount Sold \$ 4,506,807 USD
Total Remaining to be Sold \$ 0 USD or ☐ Indefinite

Clarification of Response (if Necessary):

This Form D is being filed in connection with the issuance of warrants to purchase up to an aggregate of 11,267,018 ADSs at an exercise price of \$0.40 per ADS, with each ADS representing 10 ordinary shares, no par value per share, of the Company.

14. Investors

☐ Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ 162,245 USD ☐ Estimate

Finders' Fees \$ 0 USD ☐ Estimate

Clarification of Response (if Necessary):

The placement agent (or its designees) also received warrants to purchase up to an aggregate of 394,346 ADSs at an exercise price of \$0.45 per ADS, each representing 10 ordinary shares, no par value per share, of the Company.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0 USD ☐ Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and submitting this notice.

Terms of Submission

In submitting this notice, each identified issuer is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes; or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506 (d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
PURPLE BIOTECH LTD.	/s/ Lior Fhima	Lior Fhima	Chief Financial Officer	2024-07-15

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
